1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
Lauber, T.
Roesch, P.
Marx, U.C.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
1
90.00
90.00
90.00
1.000
1.000
1.000
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C4 H7 N O4
133.103
y
ASPARTIC ACID
L-peptide linking
C3 H7 N O2 S
121.158
y
CYSTEINE
L-peptide linking
C5 H10 N2 O3
146.144
y
GLUTAMINE
L-peptide linking
C5 H9 N O4
147.129
y
GLUTAMIC ACID
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H10 N3 O2 1
156.162
y
HISTIDINE
L-peptide linking
C6 H13 N O2
131.173
y
ISOLEUCINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C6 H15 N2 O2 1
147.195
y
LYSINE
L-peptide linking
C5 H11 N O2 S
149.211
y
METHIONINE
L-peptide linking
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C5 H9 N O2
115.130
y
PROLINE
L-peptide linking
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
C4 H9 N O3
119.119
y
THREONINE
L-peptide linking
UK
J.Mol.Biol.
JMOBAK
0070
0022-2836
328
205
10.1016/S0022-2836(03)00245-6
12684009
Homologous Proteins with Different Folds: The Three-Dimensional Structures of Domains 1 and 6 of the Multiple Kazal-Type Inhibitor Lekti
2003
10.2210/pdb1hdl/pdb
pdb_00001hdl
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
DISULFIDE BRIDGES BETWEEN CYS 8 AND CYS 44, AND BETWEEN CYS 21 AND CYS 41
6491.618
SERINE PROTEINASE INHIBITOR LEKTI
LEKTI DOMAIN ONE
1
man
polymer
HF6478
no
no
KNEDQEMCHEFQAFMKNGKLFCPQDKKFFQSLDGIMFINKCATCKMILEKEAKSQ
KNEDQEMCHEFQAFMKNGKLFCPQDKKFFQSLDGIMFINKCATCKMILEKEAKSQ
A
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
HUMAN
I.E. VAGINAL EPITHELIUM
sample
9606
HOMO SAPIENS
CYTOPLASM
562
ESCHERICHIA COLI
ORIGAMI (DE3)
PET32A
pdbx_database_status
pdbx_nmr_software
database_2
pdbx_database_status
repository
Initial release
Version format compliance
Version format compliance
Data collection
Other
Database references
Other
1
0
2001-11-15
1
1
2011-05-08
1
2
2011-07-13
1
3
2020-01-15
1
4
2023-06-14
_pdbx_database_status.status_code_cs
_pdbx_database_status.status_code_mr
_pdbx_nmr_software.name
_database_2.pdbx_DOI
_database_2.pdbx_database_accession
_pdbx_database_status.status_code_nmr_data
LEKTI DOMAIN SIX (HF7665)
HELIX
DETERMINATION METHOD: AUTHOR PROVIDED.
SHEET
DETERMINATION METHOD: AUTHOR PROVIDED.
PDBE
Y
PDBE
2000-11-16
REL
REL
REL
REL
THE SEQUENCE FOR RESIDUES A 2 TO A 5 ARE IN CONFLICT
WITH THE SWISS-PROT SEQUENCE DATABASE AND HAVE BEEN
DESCRIBED BY MAEGERT H.-J.,J.BIOL.CHEM. (1999)
THE STRUCTURE WAS DETERMINED USING STANDARD NMR TECHNIQUES ON 15N-LABELED AND UNLABELED HF6478
LOWEST ENERGY
60
21
2D-TOCSY
2D-NOESY
2D-COSY
1H
15N-HSQC
HNHA
3D-1H
15N-TOCSY-HSQC
3D-1H
15N-NOESY-HSQC
3D-1H
15N/1H
15N-HMQC-NOESY-HSQC
4.5
pH
1
atm
298
K
simulated annealing
3
BRUNGER
refinement
X-PLOR
3.851
structure solution
NDEE
structure solution
NMRView
4.1.0
structure solution
X-PLOR
3.851
600
Bruker
DRX
LYS
1
n
1
LYS
1
A
ASN
2
n
2
ASN
2
A
GLU
3
n
3
GLU
3
A
ASP
4
n
4
ASP
4
A
GLN
5
n
5
GLN
5
A
GLU
6
n
6
GLU
6
A
MET
7
n
7
MET
7
A
CYS
8
n
8
CYS
8
A
HIS
9
n
9
HIS
9
A
GLU
10
n
10
GLU
10
A
PHE
11
n
11
PHE
11
A
GLN
12
n
12
GLN
12
A
ALA
13
n
13
ALA
13
A
PHE
14
n
14
PHE
14
A
MET
15
n
15
MET
15
A
LYS
16
n
16
LYS
16
A
ASN
17
n
17
ASN
17
A
GLY
18
n
18
GLY
18
A
LYS
19
n
19
LYS
19
A
LEU
20
n
20
LEU
20
A
PHE
21
n
21
PHE
21
A
CYS
22
n
22
CYS
22
A
PRO
23
n
23
PRO
23
A
GLN
24
n
24
GLN
24
A
ASP
25
n
25
ASP
25
A
LYS
26
n
26
LYS
26
A
LYS
27
n
27
LYS
27
A
PHE
28
n
28
PHE
28
A
PHE
29
n
29
PHE
29
A
GLN
30
n
30
GLN
30
A
SER
31
n
31
SER
31
A
LEU
32
n
32
LEU
32
A
ASP
33
n
33
ASP
33
A
GLY
34
n
34
GLY
34
A
ILE
35
n
35
ILE
35
A
MET
36
n
36
MET
36
A
PHE
37
n
37
PHE
37
A
ILE
38
n
38
ILE
38
A
ASN
39
n
39
ASN
39
A
LYS
40
n
40
LYS
40
A
CYS
41
n
41
CYS
41
A
ALA
42
n
42
ALA
42
A
THR
43
n
43
THR
43
A
CYS
44
n
44
CYS
44
A
LYS
45
n
45
LYS
45
A
MET
46
n
46
MET
46
A
ILE
47
n
47
ILE
47
A
LEU
48
n
48
LEU
48
A
GLU
49
n
49
GLU
49
A
LYS
50
n
50
LYS
50
A
GLU
51
n
51
GLU
51
A
ALA
52
n
52
ALA
52
A
LYS
53
n
53
LYS
53
A
SER
54
n
54
SER
54
A
GLN
55
n
55
GLN
55
A
author_defined_assembly
1
monomeric
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
x,y,z
identity operation
0.0000000000
0.0000000000
0.0000000000
A
N
LYS
16
A
N
LYS
16
A
O
LYS
19
A
O
LYS
19
1
A
A
H
O
LYS
LYS
16
19
1.54
1
A
A
O
H
PHE
PHE
11
14
1.55
1
A
A
O
H
LYS
CYS
40
44
1.56
1
A
A
O
H
LYS
PHE
26
29
1.59
2
A
A
H
O
LYS
LYS
16
19
1.54
2
A
A
O
H
PHE
PHE
11
14
1.54
2
A
A
O
H
LYS
CYS
40
44
1.55
3
A
A
H
O
LYS
LYS
16
19
1.53
3
A
A
O
H
PHE
PHE
11
14
1.55
3
A
A
O
H
LYS
CYS
40
44
1.57
3
A
A
O
H
SER
ILE
31
35
1.58
4
A
A
O
H
PHE
PHE
11
14
1.55
4
A
A
O
H
PHE
SER
28
31
1.58
4
A
A
H
O
LYS
LYS
16
19
1.58
5
A
A
O
H
LYS
CYS
40
44
1.54
5
A
A
O
H
PHE
PHE
11
14
1.55
5
A
A
H
O
LYS
LYS
16
19
1.57
6
A
A
O
H
PHE
SER
28
31
1.57
6
A
A
O
H
PHE
PHE
11
14
1.58
6
A
A
O
H
LYS
CYS
40
44
1.58
7
A
A
H
O
LYS
LYS
16
19
1.51
7
A
A
O
H
PHE
PHE
11
14
1.56
7
A
A
O
H
PHE
CYS
37
41
1.59
8
A
A
H
O
LYS
LYS
16
19
1.54
8
A
A
O
H
PHE
PHE
11
14
1.55
8
A
A
O
H
LYS
CYS
40
44
1.56
8
A
A
O
H
PHE
SER
28
31
1.58
9
A
A
O
H
LYS
CYS
40
44
1.54
9
A
A
H
O
LYS
LYS
16
19
1.55
9
A
A
O
H
PHE
PHE
11
14
1.56
9
A
A
O
H
GLN
MET
5
7
1.57
10
A
A
O
H
PHE
PHE
11
14
1.57
10
A
A
O
H
PHE
CYS
37
41
1.58
11
A
A
O
H
LYS
CYS
40
44
1.54
11
A
A
H
O
LYS
LYS
16
19
1.56
11
A
A
O
H
PHE
PHE
11
14
1.56
11
A
A
O
H
PHE
CYS
37
41
1.56
12
A
A
O
H
PHE
PHE
11
14
1.56
12
A
A
O
H
LYS
CYS
40
44
1.59
13
A
A
H
O
LYS
LYS
16
19
1.52
13
A
A
O
H
PHE
PHE
11
14
1.55
14
A
A
H
O
LYS
LYS
16
19
1.55
14
A
A
O
H
PHE
PHE
11
14
1.56
14
A
A
O
H
LYS
PHE
26
29
1.56
14
A
A
O
H
SER
ILE
31
35
1.59
15
A
A
O
H
LYS
CYS
40
44
1.53
15
A
A
O
H
PHE
PHE
11
14
1.54
15
A
A
H
O
LYS
LYS
16
19
1.58
15
A
A
O
H
LYS
PHE
26
29
1.60
16
A
A
O
H
PHE
PHE
11
14
1.55
17
A
A
O
H
LYS
CYS
40
44
1.56
17
A
A
O
H
PHE
PHE
11
14
1.57
17
A
A
H
O
LYS
LYS
16
19
1.57
18
A
A
O
H
PHE
PHE
11
14
1.57
18
A
A
H
O
LYS
LYS
16
19
1.59
19
A
A
O
H
PHE
PHE
11
14
1.56
19
A
A
O
H
LYS
CYS
40
44
1.56
19
A
A
O
H
PHE
CYS
37
41
1.58
20
A
A
O
H
PHE
PHE
11
14
1.55
20
A
A
O
H
SER
ILE
31
35
1.56
20
A
A
O
H
GLN
MET
5
7
1.57
20
A
A
O
H
PHE
SER
28
31
1.58
21
A
A
O
H
PHE
PHE
11
14
1.56
21
A
A
O
H
SER
ILE
31
35
1.58
1
A
PRO
23
-63.82
84.45
1
A
GLN
24
-121.70
-83.94
1
A
CYS
41
-65.26
-71.61
2
A
MET
7
-41.60
165.40
2
A
PRO
23
-65.30
79.09
2
A
GLN
24
-122.19
-112.96
3
A
GLN
5
69.86
-71.64
3
A
GLU
6
-69.04
59.73
3
A
PRO
23
-61.99
83.12
3
A
GLN
24
-126.56
-77.11
3
A
CYS
41
-54.33
-71.80
4
A
MET
7
58.81
-142.99
4
A
PRO
23
-62.35
73.86
4
A
ASP
25
-165.03
64.67
4
A
CYS
41
-54.66
-72.44
5
A
ASP
4
-152.61
84.90
5
A
PRO
23
-62.43
82.69
5
A
GLN
24
-125.63
-76.48
5
A
CYS
41
-60.61
-73.48
6
A
ASP
4
46.20
24.78
6
A
GLU
6
-144.19
25.62
6
A
PRO
23
-62.05
83.11
6
A
GLN
24
-112.38
-79.61
7
A
HIS
9
-135.80
-39.39
7
A
PHE
21
-103.48
73.58
7
A
PRO
23
-61.56
82.54
7
A
GLN
24
-126.02
-78.35
7
A
CYS
41
-53.86
-75.61
8
A
PHE
21
-101.73
64.16
8
A
PRO
23
-65.19
84.27
8
A
ASP
25
-179.97
55.04
9
A
GLN
5
57.84
-85.01
9
A
GLU
6
-68.53
60.70
9
A
MET
7
-39.56
-30.55
9
A
HIS
9
-132.14
-44.86
9
A
PRO
23
-61.58
82.74
9
A
GLN
24
-120.77
-86.13
10
A
GLN
5
75.44
-47.58
10
A
GLU
6
-38.79
-30.05
10
A
CYS
8
-45.29
-78.73
10
A
HIS
9
47.93
24.67
10
A
LYS
16
-105.31
77.64
10
A
PRO
23
-61.12
82.06
10
A
GLN
24
-113.45
-78.31
10
A
CYS
41
-42.61
-73.46
11
A
GLU
6
-141.72
44.67
11
A
PRO
23
-62.01
73.79
11
A
ASP
25
-171.81
61.00
11
A
CYS
41
-47.04
-72.25
12
A
ASP
4
-110.02
55.97
12
A
GLN
5
-114.77
64.77
12
A
PHE
21
-101.30
74.74
12
A
PRO
23
-65.46
75.75
12
A
GLN
24
-119.98
-113.29
13
A
MET
7
59.19
-160.70
13
A
PHE
21
-103.49
69.56
13
A
PRO
23
-62.41
83.98
13
A
GLN
24
-125.97
-78.72
13
A
PHE
29
-49.76
-19.49
13
A
CYS
41
-50.62
-74.57
14
A
ASP
4
-119.41
-102.66
14
A
GLN
5
176.62
-34.62
14
A
PRO
23
-63.19
72.70
14
A
GLN
24
-105.38
-91.18
15
A
GLU
6
-156.83
33.53
15
A
PRO
23
-62.28
82.00
15
A
GLN
24
-115.54
-91.26
15
A
LYS
27
-39.83
-27.54
16
A
PRO
23
-63.03
75.29
16
A
GLN
24
-120.22
-85.71
16
A
CYS
41
-58.63
-74.17
17
A
PRO
23
-59.20
78.17
17
A
GLN
24
-105.94
-89.29
17
A
CYS
41
-41.09
-72.70
18
A
GLN
5
-177.14
-32.58
18
A
HIS
9
-162.49
-36.67
18
A
PRO
23
-66.08
82.75
18
A
GLN
24
-128.96
-110.44
19
A
HIS
9
-127.35
-50.70
19
A
PRO
23
-62.61
83.86
19
A
GLN
24
-124.29
-78.76
19
A
CYS
41
-50.22
-75.34
20
A
GLN
5
58.82
-85.26
20
A
GLU
6
-68.76
60.61
20
A
PHE
21
-107.01
75.72
20
A
PRO
23
-61.83
70.36
20
A
GLN
24
-106.91
-74.02
21
A
GLN
5
63.33
-70.52
21
A
MET
7
56.16
104.99
21
A
PRO
23
-62.38
82.11
LEKTI domain one
1
N
N
A
GLN
12
A
GLN
12
HELX_P
A
PHE
14
A
PHE
14
1
1
3
A
LYS
26
A
LYS
26
HELX_P
A
GLN
30
A
GLN
30
1
2
5
A
LEU
32
A
LEU
32
HELX_P
A
ALA
52
A
ALA
52
1
3
21
disulf
2.020
A
CYS
8
A
SG
CYS
8
1_555
A
CYS
44
A
SG
CYS
44
1_555
disulf
2.020
A
CYS
22
A
SG
CYS
22
1_555
A
CYS
41
A
SG
CYS
41
1_555
PUTATIVE SERINE PROTEINASE INHIBITOR
PUTATIVE SERINE PROTEINASE INHIBITOR
ISK5_HUMAN
UNP
1
Q9NQ38
23
77
1HDL
1
55
Q9NQ38
A
1
1
55
1
ASP
variant
ASN
2
1HDL
A
Q9NQ38
UNP
24
2
1
SER
variant
GLU
3
1HDL
A
Q9NQ38
UNP
25
3
1
LEU
variant
ASP
4
1HDL
A
Q9NQ38
UNP
26
4
1
SER
variant
GLN
5
1HDL
A
Q9NQ38
UNP
27
5
2
anti-parallel
A
MET
15
A
MET
15
A
LYS
16
A
LYS
16
A
LYS
19
A
LYS
19
A
LEU
20
A
LEU
20
1
P 1